Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report.

Tytuł:
Genomic architecture and treatment outcome in pediatric acute myeloid leukemia: a Children's Oncology Group report.
Autorzy:
Vujkovic M; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA.
Attiyeh EF; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA.
Ries RE; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Goodman EK; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA.
Ding Y; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA.
Kavcic M; Unit of Oncology and Hematology, University Medical Centre, Ljubljana, Slovenia.
Alonzo TA; Keck School of Medicine, University of Southern California, Los Angeles, CA.
Wang YC; Children's Oncology Group, Monrovia, CA.
Gerbing RB; Children's Oncology Group, Monrovia, CA.
Sung L; Hospital for Sick Kids, Toronto, ON, Canada.
Hirsch B; Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN.
Raimondi S; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA.; St Jude Children's Research Hospital, Memphis, TN; and.
Gamis AS; Division of Hematology/Oncology/Bone Marrow Transplantation, Children's Mercy Hospitals & Clinics, Kansas City, MO.
Meshinchi S; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA.
Aplenc R; Division of Oncology, Children's Hospital of Philadelphia, Philadelphia, PA.
Źródło:
Blood [Blood] 2017 Jun 08; Vol. 129 (23), pp. 3051-3058. Date of Electronic Publication: 2017 Apr 14.
Typ publikacji:
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
Język:
English
Imprint Name(s):
Publication: 2021- : [New York] : Elsevier
Original Publication: New York, Grune & Stratton [etc.]
MeSH Terms:
DNA Copy Number Variations*
Leukemia, Myeloid, Acute/*genetics
Leukemia, Myeloid, Acute/*therapy
Child ; Child, Preschool ; Cohort Studies ; DNA, Neoplasm/genetics ; Disease-Free Survival ; Female ; Genetic Markers ; Genotype ; Humans ; Infant ; Kaplan-Meier Estimate ; Leukemia, Myeloid, Acute/mortality ; Male ; Prognosis ; Proportional Hazards Models ; Risk Factors ; Treatment Outcome
References:
Cancer. 2012 Feb 1;118(3):761-9. (PMID: 21766293)
Blood. 2006 May 15;107(10):3847-53. (PMID: 16434492)
Cancer Res. 2016 Apr 15;76(8):2197-205. (PMID: 26941285)
BMC Genomics. 2009 Dec 08;10:588. (PMID: 19995423)
Cancer Res. 2017 Apr 1;77(7):1697-1708. (PMID: 28108507)
Leukemia. 2005 Dec;19(12):2101-16. (PMID: 16136167)
Blood. 2008 Feb 1;111(3):1044-53. (PMID: 18000167)
Cancer Genet. 2015 Jul-Aug;208(7-8):408-13. (PMID: 26163103)
Pediatr Blood Cancer. 2011 Aug;57(2):204-9. (PMID: 21504050)
Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12944-9. (PMID: 19651601)
Blood. 2012 Aug 23;120(8):1581-8. (PMID: 22649108)
Nature. 2008 Nov 6;456(7218):66-72. (PMID: 18987736)
Leukemia. 2006 Jul;20(7):1310-3. (PMID: 16628191)
Oncol Rep. 2012 Oct;28(4):1503-11. (PMID: 22858860)
Oncogene. 2006 Oct 5;25(45):6147-52. (PMID: 16682951)
Blood. 2006 Dec 1;108(12):3654-61. (PMID: 16912228)
N Engl J Med. 2009 Sep 10;361(11):1058-66. (PMID: 19657110)
Nucleic Acids Res. 2008 Nov;36(19):e126. (PMID: 18784189)
Nat Genet. 2013 Oct;45(10):1134-40. (PMID: 24071852)
Leukemia. 2013 Jul;27(7):1548-57. (PMID: 23455394)
Blood. 2012 Mar 8;119(10):e67-75. (PMID: 22234698)
Blood. 2008 Aug 1;112(3):814-21. (PMID: 18490517)
Blood. 2008 Oct 15;112(8):3391-402. (PMID: 18663147)
Leukemia. 2011 Jun;25(6):1039-42. (PMID: 21358716)
Nat Biotechnol. 2011 May 08;29(6):512-20. (PMID: 21552272)
Genes Chromosomes Cancer. 2001 Aug;31(4):382-9. (PMID: 11433529)
J Exp Med. 2013 Feb 11;210(2):321-37. (PMID: 23359069)
Mol Cell Probes. 2011 Oct-Dec;25(5-6):206-11. (PMID: 21914469)
Blood. 2011 May 12;117(19):5019-32. (PMID: 21300984)
J Clin Oncol. 2014 Sep 20;32(27):3021-32. (PMID: 25092781)
Expert Rev Mol Diagn. 2001 Nov;1(4):428-33. (PMID: 11901857)
Blood. 2009 Jun 25;113(26):6558-66. (PMID: 19304957)
Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16910-5. (PMID: 20837533)
Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):20007-12. (PMID: 18077431)
Grant Information:
R01 CA114563 United States CA NCI NIH HHS; R01 CA133881 United States CA NCI NIH HHS; U10 CA180899 United States CA NCI NIH HHS
Molecular Sequence:
ClinicalTrials.gov NCT01407757; NCT00070174; NCT00003790; NCT01407757; NCT00070174; NCT00003790
Substance Nomenclature:
0 (DNA, Neoplasm)
0 (Genetic Markers)
Entry Date(s):
Date Created: 20170416 Date Completed: 20170822 Latest Revision: 20210202
Update Code:
20240105
PubMed Central ID:
PMC5465840
DOI:
10.1182/blood-2017-03-772384
PMID:
28411282
Czasopismo naukowe
Childhood acute myeloid leukemia (AML) is frequently characterized by chromosomal instability. Approximately 50% of patients have disease relapse, and novel prognostic markers are needed to improve risk stratification. We performed genome-wide genotyping in 446 pediatric patients with de novo AML enrolled in Children's Oncology Group (COG) studies AAML0531, AAML03P1, and CCG2961. Affymetrix and Illumina Omni 2.5 platforms were used to evaluate copy-number alterations (CNAs) and determine their associations with treatment outcome. Data from Affymetrix and Illumina studies were jointly analyzed with ASCAT and GISTIC software. An average of 1.14 somatically acquired CNAs per patient were observed. Novel reoccurring altered genomic regions were identified, and the presence of CNAs was found to be associated with decreased 3-year overall survival (OS), event-free survival (EFS), and relapse risk from the end of induction 1 (hazard ratio [HR], 1.7; 95% confidence interval [CI], 1.2-2.4; HR, 1.4; 95% CI, 1.0-1.8; and HR, 1.4; 95% CI, 1.0-2.0, respectively). Analyses by risk group demonstrated decreased OS and EFS in the standard-risk group only (HR, 1.9; 95% CI, 1.1-3.3 and HR, 1.7; 95% CI, 1.1-2.6, respectively). Additional studies are required to test the prognostic significance of CNA presence in disease relapse in patients with AML. COG studies AAML0531, AAML03P1, and CCG2961 were registered at www.clinicaltrials.gov as #NCT01407757, #NCT00070174, and #NCT00003790, respectively.
(© 2017 by The American Society of Hematology.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies